SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)
ALXN 182.500.0%Jul 28 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (379)11/10/2003 1:48:56 PM
From: rkrw  Read Replies (2) of 824
 
I'd guess the probably not-so-prospectively defined secondary endpoints of death at 4 and 30 days were much closer to random than the .096 at 90 days.

I tried to reverse calculate what possible death outcomes were and came up with
4 Day: 9 drug, 10 Placebo
30 Day: 27 Drug, 30 Placebo
90 Day: 56 Drug, 74 Placebo

If I remember correctly for the phase II the gap in death at 90 days had narrowed slightly from 30 days.

Hate to say it, but I don't think they're going to get approval without a second, larger phase III. If so, that could push approval back to at least 2007 imo.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News